| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 24 Apr 2025 | 24 Apr 2025 |
| We wish to inform you that the Board of Directors of the Company at their meeting held today i.e Thursday, April 24, 2025 has inter alia considered and approved the following : 1. Allotment of 8,48,220 Equity Shares 2.Allotment of 6,50,000 fully convertible warrants | ||
| Board Meeting | 26 Feb 2025 | 21 Feb 2025 |
| MEDICAMEN BIOTECH LTD.-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 26/02/2025 inter alia to consider and approve We wish to inform you that a meeting of the Board of Directors is scheduled to be held on Wednesday February 26 2025 inter alia to consider and approve a proposal for raising of funds by way of issuance of one or more instruments including equity shares/convertible securities either by way of Preferential Issue/Right Issue/QIP or any other mode. Announcement under Regulation 30 (LODR)- Issue of Securities (As Per BSE Announcement Dated on: 26/02/2025) | ||
| Board Meeting | 11 Feb 2025 | 4 Feb 2025 |
| MEDICAMEN BIOTECH LTD.-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/02/2025 inter alia to consider and approve the standalone and consolidated unaudited financial results of the company for the quarter ended on Decmeber 31 2024. Appointment of Mr. Chandan Kumar as Chief Financial Officer and Key Managerial Personnel of the Company w.e.f February 11, 2025 Outcome of Board meeting held on 11.02.2025 (As per BSE Announcement Dated on 11/02/2025) | ||
| Board Meeting | 14 Nov 2024 | 7 Nov 2024 |
| MEDICAMEN BIOTECH LTD.-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2024 inter alia to consider and approve Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and half year ended on September 30 2024. Outcome of the Board Meeting held on 14-11-2024 (As Per BSE Announcement dated on 14.11.2024) | ||
| Board Meeting | 13 Aug 2024 | 7 Aug 2024 |
| MEDICAMEN BIOTECH LTD.-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/08/2024 inter alia to consider and approve Un-audited Financial Results (Standalone & Consolidated) for the quarter ended on June 30 2024 and for draft Annual Report for the FY 2023-24 Financial Results for the quarter ended on 30.06.2024 (As per BSE Announcement Dated on 13/08/2024) | ||
| Board Meeting | 29 May 2024 | 21 May 2024 |
| MEDICAMEN BIOTECH LTD.-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2024 inter alia to consider and approve Audited Financial Results (Standalone & Consolidated) for the quarter & year ended on 31.03.2024 and to approve Final Dividend for the FY 2023-24. Approval of Audited Financial Results for the quarter ended on 31.03.2024 and recommendation of Final Dividend for the FY 2023-24 (As Per BSE Announcement Dated on 29/05/2024) | ||
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
